Newly-diagnosed APL (de Novo or Therapy-related) Clinical Trial
Official title:
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
The registry aims to document epidemiologic data, treatment and long-term outcome as well as quality of life of patients with APL. Additionally, a biobanking project for further translational studies is integrated. Prospective population-based non-interventional and non-randomized multicenter registry.
- collection of epidemiological data for APL: age distribution, prognostic factors, distribution of subgroups, incidence - documentation of efficacy and safety of the first line and salvage therapy in APL including - documentation of minimal residual disease (MRD) - correlation of clinical outcomes with chosen therapy - collection and evaluation of quality of life - validation of published prognostic factors / new potential prognostic factors - acquisition of bone marrow, peripheral blood and buccal swab samples for biobanking and translational studies under the umbrella of the specific study-group biobanking concepts ;